Executing a complex pharma divestment

A global, Asia headquartered pharmaceutical company acquired a broad product portfolio to strengthen its in-home manufacturing and core product range.

The strategic plan for the non-core assets was to optimize their value before divesting them. We partnered with the client after a preliminary buyer agreement to convert strategic intent into a controlled, operationally sound divestment, preserving value, ensuring regulatory compliance, and protecting supply continuity across multiple markets.

THE CHALLENGE

The hidden complexities behind a signed deal

The divestment presented a high-risk, high-complexity execution problem driven by:

Geographic scope across multiple markets
Dozens of third-party manufacturing partners
A complex regulatory and quality footprint
Ongoing supply, pharmacovigilance, and contractual obligations
Limited internal expertise related to corporate divestments

Although a buyer had been identified and a preliminary agreement was in place, the program faced material risks:

missed contractual milestones,
regulatory non-compliance,
disrupted supply, and
potential reputational damage.

Left unmanaged, these risks threatened significant value leakage after signing.

OUR SOLUTION

Structuring the transition end-to-end

Our team of consultants structured and executed the transition end-to-end. We supported the seller (and indirectly also the buyer) through the most critical phase, focusing on three integrated pillars to convert the signed agreement into a reliable operational reality:

1. Translating agreements into operations

We converted commercial and legal terms into executable operational arrangements. This included negotiating and finalizing all subsidiary agreements required to operationalize the deal across:

manufacturing,
supply,
quality,
regulatory, and
commercial domains.

Each agreement was drafted with clear operational triggers, handover criteria, and escalation pathways to eliminate ambiguity at transfer.

2. End-to-end transition planning

We designed a phased, market-by-market transition plan rather than treating divestment as a single event. The plan covered:

Contractual obligations and milestone sequencing
Regulatory pathways and submission timelines
Market-by-market handovers
Manufacturing and supply continuity plans
Ongoing pharmacovigilance and quality obligations

This approach ensured that both parties understood not only what was being transferred, but precisely how and when responsibilities would shift.

3. Coordinating a highly complex ecosystem

We established a program-level operating model to coordinate hundreds of stakeholders across internal functions, external partners, and market teams. Our consultants provided a horizontal view to align interdependent plans, resolve conflicts early, and maintain a single source of truth for decisions and timelines.

Throughout the engagement, we focused on safeguarded deal value by proactively identifying and mitigating downstream risks – the kind that often surface only after deal signing.

THE RESULTS

Delivering a divestment that held its value

Our client’s divestment closed with operational continuity preserved and value protected. Key outcomes included:

Accelerated regulatory transition that shortened the timeline by 6 to 8 months
Structured, controlled handovers across multiple markets with clear acceptance criteria
Reduced risk of value leakage from missed obligations, penalties, or supply interruptions
Transparent leadership visibility on when and how responsibilities would end
Strategic alignment enabling the client to focus on core manufacturing capabilities

This engagement demonstrates that disciplined, operationally focused execution is essential to realize the value of complex divestments. By translating agreements into actionable plans, sequencing market and regulatory activities, and coordinating a broad stakeholder ecosystem, we turned a high-risk transaction into a controlled, value-preserving outcome.